Centific and mimik partner to revolutionize AI-powered smart spaces with edge intelligence
OAKLAND, Calif., March 19, 2025 /PRNewswire/ -- Centific, a frontier AI data foundry platform company accelerating businesses' AI and mimik, a leader in device-first continuum AI (DFC-AI), today announced a strategic partnership to introduce a groundbreaking AI-powered smart space solution. By integrating mimik's edge-native agentic runtime with Centific's AI frontier AI data foundry platform, the collaboration brings an unprecedented level of real-time video intelligence, cost efficiency, and data privacy. This new paradigm unlocks proactive threat detection, behavioral insights, and scalable multi-camera AI processing without the traditional reliance on centralized cloud infrastructure.
This partnership sets a new standard for edge-enabled AI in smart spaces.
The Centific-mimik solution pioneers an adaptive compute continuum, dynamically distributing AI workloads across edge devices, servers, and private cloud environments based on operational needs. This edge-first strategy eliminates cloud latency, reduces bandwidth overhead, and helps ensure AI-driven insights are context-aware, responsive, and secure within an organization's operational framework.
By leveraging mimik's scalable Open Edge (OE) platform alongside Centific's frontier AI data foundry platform, the solution enables:
Federated AI processing across thousands of cameras with minimized data movement, optimizing edge execution.
Hybrid cloud integration to balance real-time decision-making at the edge with deeper analytics in secure cloud environments.
Autonomous AI agents leveraging multimodal video-linguistic AI models to provide proactive situational awareness.
Event-driven intelligence that enhances security and operational efficiency without dependency on constant connectivity.
Centific's frontier AI data foundry platform elevates edge AI capabilities
Centific's frontier AI data foundry platform plays a critical role in optimizing AI-driven video intelligence by:
Supporting 100s of use cases across industries with adaptable AI workflows and multi-model processing.
Leveraging 100+ pre-configured templates for rapid and efficient data extraction, localization, and contextualization.
Addressing data scarcity and privacy concerns by generating realistic synthetic datasets.
Helping to ensure data integrity with AI-driven validation and human-in-the-loop (HITL) oversight in quality assurance processes.
Enforcing safe AI practices with data privacy and compliance mechanisms on a global scale.
Providing enterprise-ready AI models that maximize performance and minimize costs through advancements in LLM fine-tuning and model optimization.
Centific's frontier AI data foundry platform integrates seamlessly with mimik's edge intelligence platform, helping to ensure that AI models remain contextually adaptive, continuously refined, and efficiently deployed across diverse environments.
'At Centific,' said Venkat Rangapuram, CEO of Centific, 'we are committed to harnessing AI to create safer communities by making AI-driven solutions more accessible and affordable across all devices. Our collaboration with mimik reinforces this vision, bringing edge intelligence and real-time AI analytics to the forefront of public safety. By leveraging our frontier AI data foundry platform-driven approach, we can help ensure that AI is not only scalable and cost-effective but also privacy-conscious and contextually adaptive. This marks a new era where organizations can deploy intelligent security solutions with heightened situational awareness while reducing infrastructure costs. Together, we are making AI work for everyone, everywhere.'
'mimik's DFC-AI is transforming enterprise AI deployments,' added Fay Arjomandi, Founder & CEO of mimik. 'By harnessing the power of edge intelligence and federated AI, we enable organizations to execute agentic AI workloads efficiently, even in connectivity-limited environments.'
This partnership is the future of AI-powered smart spaces
This partnership marks a pivotal shift in AI-driven security and public safety. By reducing reliance on cloud infrastructure and leveraging intelligent edge computing, organizations can now deploy scalable, privacy-conscious AI systems that operate with heightened situational awareness and reduced operational costs.
About Centific:
Centific lives at the forefront of AI innovation, specializing in platform-driven solutions that transform raw data into fuel for the future of AI. By elevating data quality and accelerating AI deployments, Centific empowers businesses to build smarter, safer, and more scalable AI solutions. The company's commitment to collaboration spans academia, industry, and technology, with a focus on sustainable practices that address real-world needs.
Join Centific in redefining the AI landscape at www.centific.com and follow us on LinkedIn.
About mimik:
mimik is for Agentix Native, the 5th Element of AI. We have solved the most complex challenges in AI software, including AI Continuum on Continuum Compute, Parallel AI, and the Network Offline-First Distributed Dynamic Agentic Service Mesh Problem. Our technology enables seamless, scalable, and efficient agentic workflows, automation, and autonomous decision-making across all compute layers.
By accelerating AI adoption and enabling intelligent workflow operations, mimik ensures enterprises maintain full control, security, and efficiency. With Zero-Trust Security and optimized operational efficiency in both energy and cost, businesses can scale AI while staying resilient and adaptable in an ever-evolving digital landscape. mimik, Your ROI for AI.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Johnson & Johnson unveils first-in-human results for pasritamig, showing early anti-tumor activity in prostate cancer
Pasritamig, a first-in-class bispecific T-cell-engaging antibody, shows potential in mCRPC with outpatient dosing designed for the community setting Data show low rates of treatment-related adverse events, signaling human kallikrein 2 (KLK2) as a novel, highly specific target CHICAGO, June 1, 2025 /PRNewswire/ -- Johnson & Johnson announced today new data from a Phase 1 study evaluating pasritamig (JNJ-78278343), a first-in-class bispecific antibody that activates T-cells to harness the body's immune system against prostate cancer cells, showing promise in patients with advanced disease who have progressed after multiple lines of therapy. These first data on pasritamig, from the first-in-human study, demonstrate that pasritamig appears well-tolerated and exhibits a promising antitumor activity in patients with metastatic castration-resistant prostate cancer (mCRPC), highlighting the potential of KLK2 as a novel target for T-cell engagement in advanced disease.1 These data were presented as an oral presentation (Abstract #5017) at the 2025 American Society of Clinical Oncology Annual Meeting and published simultaneously in The Journal of Clinical Oncology. Pasritamig is a novel T-cell engager designed to bind both CD3 on T-cells and KLK2—a prostate-specific antigen with minimal expression outside of the prostate. Pasritamig activates T-cells by binding to CD3 and directing them to KLK2- expressing tumor cells, engaging the body's immune system to specifically target these cancerous cells. This differentiated approach aims to deliver a targeted treatment for patients with advanced prostate cancer, while potentially reducing the high-grade toxicities historically associated with T-cell engagers. "These first-in-human results for pasritamig are highly encouraging, demonstrating that KLK2 is a viable target for T-cell engagers in metastatic castration-resistant prostate cancer," said Capucine Baldini*, M.D., Ph.D., Drug Development Department (DITEP), Institut Gustave Roussy, and presenting author. "The data show a promising safety profile, with manageable adverse events and no AEs leading to treatment discontinuations or ICANS observed, with 40 percent of patients having no treatment-related AEs at all. Given the limited treatment options for mCRPC, these findings support further investigation of pasritamig and the role of KLK2-targeted T-cell therapies as a potential new approach for patients with aggressive disease." "Metastatic castration-resistant prostate cancer remains one of the most difficult stages of prostate cancer to treat, particularly for patients who haven't responded well to previous treatments," said Jeff Infante, M.D., Vice President of Early Clinical Development and Translational Research at Johnson & Johnson Innovative Medicine. "This investigational approach underscores our commitment to developing innovative and practice-changing medicines that are well-tolerated and can be easily administered in community practice settings." The Phase 1 first-in-human study (NCT04898634) evaluated 174 patients with ages ranging from 36 to 89 years old and on average having received four prior therapies (range 1-13). The recommended phase 2 dose (RP2D) of pasritamig was 3.5mg on day 1, 18mg on day 8, 300mg intravenously on day 15 and then once every six weeks. The RP2D safety group also included patients treated once every three weeks as the toxicity profiles were very similar. The RP2D efficacy group only included patients treated at the RP2D once every six weeks.1 Within the RP2D safety group (n=45), treated once every three or six weeks, 100 percent had previously received androgen receptor pathway inhibitors, 75.6 percent had undergone taxane chemotherapy, and 37.8 percent had been treated with Lutetium 177 vipivotide tetraxetan prostate-specific membrane antigen radioligand therapy.1 The most common treatment- related adverse events (TRAEs) were Grade 1/2 infusion-related reactions (24.4 percent), Grade 1 cytokine release syndrome (CRS) presenting as fever only (8.9 percent, no steroid or tocilizumab was administered) and no reports of higher grade CRS. No TRAEs leading to treatment discontinuation or dose reduction were reported and no immune effector cell-associated neurotoxicity syndrome (ICANS) was observed. Grade 3 TRAEs were infrequent with 4.4 percent of patients reporting transient AST/ALT increases and neutropenia. There were no dose-limiting toxicities reported. The favorable safety profile of the RP2D regimen enabled convenient outpatient administration on a patient-friendly, once-every-six-weeks schedule.1 Of the patients in the RP2D efficacy group (n=33), treated once every six weeks, 42.4 percent achieved a 50 percent or greater reduction in their prostate-specific antigen (PSA) levels with a median rPFS of 7.9 months (95 percent confidence interval [CI] 2.9, not estimable [NE]) and 21.2 percent of patients continuing therapy. Treatment with pasritamig showed durable disease control and rPFS that compares favorably to historical data in heavily pretreated patients with mCRPC.1 Metastatic castration-resistant prostate cancer occurs in a significant portion of prostate cancer patients, with many progressing despite initial therapies.2 Overall survival from diagnosis of mCRPC patients ranges from 13.5 to 31.6 months, and lower in patients who have progressed on therapy.3 Treatment options remain limited, underscoring the urgent need for safer and more effective therapies.4 About Pasritamig (JNJ-78278343)Pasritamig (JNJ-78278343) is an investigational T-cell-engaging bispecific antibody (bsAb) targeting human kallikrein 2 (KLK2) on prostate cancer cells and CD3 on T-cells. This approach is being evaluated in heavily pretreated patients with metastatic castration-resistant prostate cancer (mCRPC), a patient population with limited treatment options. About Metastatic Castration-Resistant Prostate Cancer (mCRPC)Metastatic castration-resistant prostate cancer (mCRPC) is a challenging and aggressive stage of prostate cancer where the disease progresses despite androgen deprivation therapy.2 Patients often experience metastasis to bones and lymph nodes, leading to poor outcomes and limited treatment options, including chemotherapy and second-line hormone therapies.5 The median overall survival ranges from 13.5 to 31.6 months depending on the site of metastasis, with a typical range of 15–36 months across the broader population.3,6 Survival rates can vary significantly depending on factors such as prior treatment history, disease burden, and response to therapy. The need for more effective treatments is critical, as the disease continues to impact a large number of men globally, with mCRPC being responsible for a substantial number of prostate cancer-related deaths. About Johnson & JohnsonAt Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at or at Follow us at @JNJInnovMed. Janssen Research & Development, LLC, Janssen Biotech, Inc., Janssen Global Services, LLC and Janssen Scientific Affairs, LLC are Johnson & Johnson companies. Cautions Concerning Forward-Looking StatementsThis press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding product development and the potential benefits and treatment impact of JNJ-78278343. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's most recent Annual Report on Form 10-K, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and in Johnson & Johnson's subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments. Source: Johnson & Johnson *Dr. Capucine Baldini has provided consulting, advisory, and speaking services to Johnson & Johnson; Dr. Baldini has not been paid for any media work. 1 Baldini, C., et al. Phase 1 Study Results of Pasritamig (JNJ-78278343) in Metastatic Castration-Resistant Prostate Cancer. 2025 American Society of Clinical Oncology Annual Meeting. June 2025.2 Scher, H. I., et al. (2016). "Treatment of castration-resistant prostate cancer: Current and future strategies." Nature Reviews Clinical Oncology, 13(10), 577-590.3 Wallace KL, Landsteiner A, Bunner SH, Engel-Nitz NM, Luckenbaugh AN. Increasing prevalence of metastatic castration-resistant prostate cancer in a managed care population in the United States. Cancer Causes Control. 2021;32(12):1365-1374. doi:10.1007/s10552-021-01484-44 Ravi P, Mateo J, Lorente D, et al. Clinical prognostic factors and management of metastatic castration-resistant prostate cancer: a population-based study. PLoS One. 2015;10(10):e0139440. doi:10.1371/ Ryan, C. J., et al. (2015). "Abiraterone acetate in metastatic prostate cancer: A new era." Journal of Clinical Oncology, 33(10), 1051-1060.6 Kawahara, T., Saigusa, Y., Yoneyama, S. et al. Development and validation of a survival nomogram and calculator for male patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate and/or enzalutamide. BMC Cancer 23, 214 (2023). Media contacts:Oncology Media Relations oncology_media_relations@ Investor contact:Lauren Johnsoninvestor-relations@ U.S. Medical Inquiries +1 800 526-7736 View original content to download multimedia: SOURCE Johnson & Johnson Sign in to access your portfolio
Yahoo
13 hours ago
- Yahoo
Casio to Release New MT-G Featuring an Original Frame Co-Created by Humans and AI
Newly Developed Structure Fusing Different Materials TOKYO, May 27, 2025 /PRNewswire/ -- Casio Computer Co., Ltd. announced today the latest addition to the G-SHOCK brand of shock-resistant watches: the MTG-B4000. This new timepiece features a distinctive frame developed in a process of collaboration between human designers and AI technology. The MTG-B4000 joins the MT-G line of timepieces, all of which utilize a unique construction that makes the most of the properties of both metal and resin. The new MTG-B4000 is a shock-resistant watch featuring a distinctive frame that was developed in a process of collaboration between human designers and generative AI and uses a combination of different materials. For the first time in a Casio consumer timepiece, generative AI technology was integrated into the development process. In pursuit of innovative craftsmanship, designers employed this advanced technology as a creative tool to explore new design possibilities and conquer the challenge of realizing a complex, unconventional structure which would have been difficult to achieve using traditional methods. Starting with design proposals from human designers, AI conducted load simulations using decades of accumulated data on shock-resistant construction for G-SHOCK. It then proposed optimal structural configurations by evaluating factors such as structural strength, material characteristics, and machinability. These AI-generated designs were refined through repeated testing and adjustments by skilled human hands, resulting in a frame that delivers the G-SHOCK signature ruggedness with a distinctive, unconventional aesthetic only achievable through AI collaboration. A new approach was also introduced by integrating the band connection parts into the frame. This allows the frame to directly absorb loads applied to the band, reducing impact on the center case and further enhancing shock resistance. The Bluetooth® word mark and logos are registered trademarks owned by Bluetooth SIG, Inc. Any use of such marks and logos by Casio Computer Co., Ltd. is under license. View original content to download multimedia: SOURCE CASIO COMPUTER CO., LTD Sign in to access your portfolio
Yahoo
a day ago
- Yahoo
Arctech to Supply 175 MW of Solar Trackers for Landmark Green Hydrogen Project in Oman
DUQM, Oman, May 31, 2025 /PRNewswire/ -- Arctech, the global leader in solar tracking, racking, and BIPV solutions, has signed a strategic contract with ACME Cleantech Solutions Pvt. Ltd. a pure play fully integrated Renewable Energy Company in India with a diversified portfolio across solar, wind, hybrid and FDRE projects to supply 175 MWp of solar trackers for the 300 MTPD Green Ammonia Project in Duqm, Oman. The project is located near the southeastern coast of Oman, a region characterized by coastal desert conditions including sandy soils, high wind speeds (up to 55 m/s), C5-level corrosion exposure, extreme temperatures and high levels of solar radiation, with an annual average of around 5,764 KWh/m2. The area's favourable climate, with high solar insolation, has made it a prime location for utility-scale solar projects. Arctech will deploy its Signature 1P Single Axis Solar Tracking System Skyline II, engineered for harsh environments, to support the solar PV component powering one of the first large-scale green hydrogen production facilities in the region. The trackers will be delivered in phases starting from July 2025. In recent years, Oman Power and Water Procurement Company (OPWP) has introduced renewable energy initiatives such as a new Concentrated Solar Power (CSP) project in Duqm. OPWP is actively working toward a diverse energy mix, aligning with the national target of sourcing 35–39% of electricity from renewables by 2040. This new partnership reinforces Oman's long-term vision and positions the Duqm region as a central hub in the global energy transition. This milestone collaboration underscores Arctech's growing role in enabling renewable energy megaprojects worldwide. The Oman installation is a flagship initiative in industrial decarbonization—integrating solar power with next-gen hydrogen fuel technologies, setting new benchmarks in clean energy integration. Moreover, Arctech has an extensive track record of experience in numerous GW-scale large projects across the globe, which instils confidence in this partnership. "We are pleased to partner with Arctech for our 300 MTPD Green Hydrogen project in Duqm, Oman. This collaboration marks an important milestone in our green hydrogen journey, and we are confident that Arctech's advanced tracking solutions and project execution capabilities will support us in achieving optimal energy efficiency and reliability under challenging coastal and high-wind site conditions," said by Vipin Aggarwal, VP of Procurement in Green Hydrogen and International Business. SOURCE Arctech Solar Sign in to access your portfolio
